Abstract
Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.
| Original language | English |
|---|---|
| Pages (from-to) | 437-446 |
| Number of pages | 10 |
| Journal | The Journal of critical illness |
| Volume | 15 |
| Issue number | 8 |
| State | Published - 2000 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Critical Care and Intensive Care Medicine
Cite this
Newer antihypertensive drug therapies : Are they better for pulmonary patients? / Nair, C. K.; Faulkner, Michele A.
In: The Journal of critical illness, Vol. 15, No. 8, 2000, p. 437-446.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Newer antihypertensive drug therapies
T2 - Are they better for pulmonary patients?
AU - Nair, C. K.
AU - Faulkner, Michele A.
PY - 2000
Y1 - 2000
N2 - Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.
AB - Diuretics are a mainstay of antihypertensive therapy for patients with asthma or chronic obstructive pulmonary disease (COPD); ability to clear airway secretions and, in patients with COPD, electrolyte and acid-base status should be monitored. β-Blockers are contraindicated in asthma and are generally better avoided in COPD; if benefit outweighs risk (as it may in cases of acute myocardial infarction, for example), start with a trial of a low dose of a β 1-selective agent without intrinsic sympathomimetic activity. α-Blockers and calcium channel blockers have favorable safety profiles with concomitant pulmonary disease; monitor oxygenation and right ventricular function in COPD patients receiving calcium channel blockers. Medications that exert inhibitory effects on the renin-angiotensin-aldosterone system may also have bronchoprotective effects. The new angiotensin II receptor blockers are an option for patients who cannot tolerate angiotensin-converting enzyme inhibitors.
UR - http://www.scopus.com/inward/record.url?scp=0033847969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033847969&partnerID=8YFLogxK
M3 - Article
VL - 15
SP - 437
EP - 446
JO - Journal of Critical Illness
JF - Journal of Critical Illness
SN - 1040-0257
IS - 8
ER -